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Summary
Bone morphogenetic protein (BMP) pathways are
required for a wide variety of developmental and ho-
meostatic decisions, and mutations in signaling com-
ponents are associated with several diseases. An
important aspect of BMP control is the extracellular
regulation of these pathways. We show that LON-2
negatively regulates a BMP-like signaling pathway
that controls body length in C. elegans. lon-2 acts ge-
netically upstreamof theBMP-like genedbl-1, and loss
of lon-2 function results in animals that are longer than
normal. LON-2 is a conserved member of the glypican
family of heparan sulfate proteoglycans, a family with
several members known to regulate growth-factor sig-
naling in many organisms. LON-2 is functionally con-
served because the Drosophila glypican gene dally
rescues the lon-2(lf) body-size defect. We show that
the LON-2 protein binds BMP2 in vitro, and a mutant
variation of LON-2 found in lon-2(e2140) animals di-
minishes this interaction. We propose that LON-2
binding to DBL-1 negatively regulates this pathway
in C. elegans by attenuating ligand-receptor interac-
tions. This is the first report of a glypican directly inter-
acting with a growth-factor pathway in C. elegans and
provides a mechanistic model for glypican regulation
of growth-factor pathways.
*Correspondence: padgett@waksman.rutgers.eduResults and Discussion
lon-2 Is a Negative Upstream Regulator of the dbl-1
Signaling Pathway
The nematodeC.elegans is an established model system
for studying the genetic and molecular regulation of BMP
signaling [1]. In C. elegans, a conserved BMP-like path-
way controls body size and male tail morphology (the
Sma/Mab pathway). Reducing pathway activity results
in animals that are about 55%–85% wild-type length,
and males have defective spicules (copulatory struc-
tures) and fused sensory rays (Table 1 [2, 3]). Overex-
pression of BMP-like dbl-1 results in long animals [2, 3].
Mutations in lon-2 produce the dbl-1 overexpression
body-size phenotype; animals are 14%–26% longer
than the wild-type, with no statistical difference between
lon-2 mutant strains (Table 2; Figures 1A and 1B). To
explore the relationship between lon-2and thedbl-1path-
way, we performed epistasis tests with lon-2(e678) and
mutant alleles of dbl-1 pathway genes. Genetically, lon-2
acts upstream of the ligand dbl-1 and a receptor, sma-6
(Table 1). Mutations in lon-1, a known target gene of the
DBL-1 pathway, also result in long animals [4, 5]. Animals
with no functional LON-1 and that overexpress dbl-1 are
longer than single-mutant animals [2, 4]. We asked
whether loss of lon-2 expression would have results sim-
ilar to those of dbl-1 overexpression in the lon-1(lf) back-
ground. lon-1(wk50);lon-2(e678) animals are also longer
thaneither single-mutant animals (Table 3). Therefore, los-
ing the function of lon-2 acts like overexpressing dbl-1.
These results also support the models that body size
depends on DBL-1 signal dosage and that the DBL-1 sig-
naling pathway does not act exclusively through lon-1.
dbl-1 pathway mutant males also frequently have tail
defects [3]. We examined lon-2(e678) male tails to see
whether lon-2 has an effect on male tail rays or spicules.
We observed no differences in lon-2(lf) males compared
to wild-type males (data not shown). Unlike Smad mu-
tant males, lon-2(e678) males mate normally [6]. Overex-
pression of lon-2(+) also has no effect on the male tail
rays or spicules (data not shown). One explanation for
this result is that lon-2 may not function in the male
tail. Studies of downstream targets of the dbl-1 pathway
(lon-1, mab-21, and mab-23) have shown that body size
and male tail development are separable [2, 4, 5, 7].
Alternatively, dosage effects may be different in the tail
than in the rest of the body. A weak sma-6(lf) receptor al-
lele gives a small phenotype without male tail defects
characteristic of stronger sma-6 alleles [8]. Overexpres-
sion of dbl-1 results in long animals with only occasional
tail defects, and the males are capable of mating [3, 9].
If saturating levels of signaling are achieved in the tail,
then excess DBL-1 signaling above this threshold in
lon-2(lf) animals may have little or no effect.
lon-2 Encodes a Novel Glypican Family Member
lon-2 alleles were originally isolated in a screen by Bren-
ner [10]. We mapped and rescued the mutant phenotype
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160of lon-2 animals with a KpnI/BamHI fragment of F35B9
(data not shown). This cosmid fragment includes the en-
tire coding region of C39E6.1, 3682 bp of its 50 promoter
sequence, and 3331 bp of its 30 sequence. Mutations in
C39E6.1 were identified in the DNA of many lon-2mutant
strains (Figure S1 in the Supplemental Data available
with this article online). Furthermore, expressing lon-2
genomic or cDNA sequences driven from the lon-2
promoter (3 kb of its 50 sequence) rescued the mutant
phenotype (Table 4 and data not shown).
LON-2 contains the motifs that define glypicans,
a type of heparan sulfate proteoglycan (HSPG). It has
an N-terminal signal sequence (predicted to be amino
acids 1–18 by Ensembl, version 39, June 2006) [11], 14
cysteines, and a putative SGXG glycosaminoglycan at-
tachment site (amino acids 442–445) (Figure S1). Glypi-
cans are also processed at the C terminus, where a gly-
cophosphoinositol (GPI) tag attaches the molecule to
extracellular membranes. LON-2 has a predicted GPI
Table 1. lon-2(e678) Is Suppressed by Ligand and Receptor
Mutant Alleles
Genotype
Body Length
(% WT 695% c.l.) n
Wild-type 100 6 2 27
dbl-1(wk70);lon-2(e678) 56 6 2 16
sma-6(wk7) 84 6 3 33
sma-6(wk7);lon-2(e678) 72 6 3 29anchor site at amino acid 489 [12]. lon-2(e2140) is a mis-
sense mutation that substitutes one of the 14 highly con-
served cysteines to a tyrosine. The phenotype of lon-
2(e2140) is indistinguishable from that of the deletion
mutant lon-2(e678) and transposon insertion mutant
lon-2(n1630) (Table 2), indicating that the cysteine resi-
due is functionally important. The otherC. elegans glypi-
can, gpn-1, has no significant phenotypic effect on body
size (Table 2). LON-2 also has an RGD motif (amino acids
348–350), which in other systems binds integrins and
other extracellular proteins. This motif is not present in
theC.briggsaeLON-2 sequence (CBP09675), but human
GPC1 does contain an RGD motif immediately after its N-
terminal signal sequence. We mutated the LON-2 RGD
site to RGA, a substitution known to destroy the integ-
rin-binding ability of RGD-containing proteins [13, 14].
This construct rescues lon-2(e678) animals (Table 5),
Table 2. lon-2(lf) Mutants Are Longer than the Wild-Type
Genotype
Body Length
(% WT 695% c.l.) n
Wild-type 100 6 2 27
gpn-1(ok377) 95 6 2 34
lon-2(e678) 114 6 2 29
lon-2(e405) 116 6 3 23
lon-2(e434) 116 6 2 39
lon-2(e955) 115 6 2 45
lon-2(e2140) 126 6 10 20
lon-2(n1630) 124 6 10 15Figure 1. The lon-2 Phenotype, Expression Pattern, and Localization
(A and B) lon-2 mutant animals are longer in length than the wild-type. Animals are representative 24 hr adults. The anterior is left; dorsal is up.
(A) shows the wild-type adult hermaphrodite. (B) shows the lon-2(e678) adult hermaphrodite.
(C and D) Expression pattern of lon-2. A lon-2 promoter fusion construct with gfp shows strong intestinal expression and weak expression in the
hypodermis of the head, body, and tail. Animals are at the L1 stage. DIC optics view (A) and fluorescence view (B). The head and the tail are in-
dicated by bars, and the arrows indicate the gonad.
(E and F) A rescuing translational-fusion construct of a full-length LON-2 to GFP is visible in intestinal cells, predominantly to the most posterior
cells. Animals are at the L1 stage. The confocal image of a non-transgenic lon-2(e678) animal shows low levels of autofluorescence (E). The con-
focal image of a transgenic lon-2(e678);wkEx87 shows fluorescence of LON-2:GFP lining intestinal cells (indicated by the long arrow) (F). The
rectum is indicated with short arrows in (E) and (F).
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161suggesting that an RGD-mediated interaction with extra-
cellular proteins is not necessary for LON-2 function.
Because HSPGs are posttranslationally modified,
we asked whether null mutations in genes encoding
enzymes that process HSPGs affect body size in
C. elegans. hse-5, hst-2, and hst-6 encode the single
C. elegans orthologs of glucuronyl C5-epimerase, 2O-
sulfotransferase, and 6O-sulfotransferase, respectively
[15]. Notably, we noticed that animals with a deletion
in any one of these genes are smaller than the wild-
type (Table 6). lon-2 is epistatic to all three heparin-
sulfate-modifying enzymes, although hse-5(lf);lon-2(lf)
animals, having a wild-type length, are intermediate in
size (Table 6). However, hse-5(lf);lon-2(lf) animals are
also frequently unhealthy and uncoordinated, and
body size may be a secondary effect of these pheno-
types. hse-5(lf) animals are only mildly uncoordinated
[15]. The epistasis results, in conjunction with single-
mutant phenotypes, are consistent with a model of
LON-2 heparan-sulfate modificaton by HSE-5, HST-2,
and HST-6 negatively regulating LON-2 activity.
LON-2 Is Required in the Hypodermis
To understand lon-2 function during development, we
first examined the lon-2 transcriptional expression pat-
tern. gfp driven by the lon-2 promoter (3 kb of its
upstream sequence) was expressed strongly in the in-
testine, most prominently in the most anterior and pos-
terior cells (Figures 1C and 1D). Expression in these
regions was observed throughout development, begin-
ning in the embryo and continuing into adulthood. Very
weak fluorescence was also seen in hypodermal cells
in the head and tail (Figures 1C and 1D).
We then asked where the LON-2 protein localized
subcellularly by generating transgenic nematode strains
expressing an internally tagged, in-frame GFP fusion
protein of LON-2. GFP was inserted at amino acid 26,
between the predicted N-terminal signal sequence and
the first conserved cysteine residue (at amino acid 43).
This construct rescues lon-2(e678) animals to the wild-
type or small (data not shown). GFP-tagged LON-2-pro-
tein fluorescence is weak and localizes to the surface of
intestinal cells, most visibly to the most posterior cells
(Figures 1E and 1F). This observation is consistent
Table 3. lon-2(e678) Shows Additivity with lon-1(wk50)
Genotype
Body Length
(% WT 695% c.l.) n
Wild-type 100 6 2 27
lon-1(wk50) 111 6 5 17
lon-1(wk50);lon-2(e678) 123 6 6 16
Table 4. lon-2(e678) Is Rescued by Wild-Type lon-2 cDNA
Genotype
Body Length
(% e678 695% c.l.) n
lon-2(e678) 100 6 2 55
Wild-type 88 6 2 27
lon-2(e678);wkEx72
[lon-2p::yk185c5]
78 6 2 17
lon-2(e678);wkEx73
[lon-2p::yk185c5]
78 6 2 32with a GPI modification of LON-2 because GPI moieties
link their proteins to the extracellular surface of cell
membranes.
Executors of the DBL-1 signaling pathway (the recep-
tor genes sma-6 and daf-4, a Smad gene, sma-3) and
a known target gene, lon-1, have a similar expression
pattern as lon-2, with strong expression in intestine
and weaker expression in the hypodermis. These genes’
products have been shown to be required in the hypo-
dermis for body-size regulation [4, 5, 8, 16–18]. We
asked whether LON-2 is also required in the hypodermis
to control body size by performing cell-type-specific
rescue experiments of body size. We found that expres-
sion of lon-2(+) in intestine with the elt-2 promoter had
little to no rescue of body size, whereas expression of
lon-2(+) in hypodermal cells by the elt-3 promoter res-
cued lon-2(e678) animals to a small phenotype (Table
7) [4]. Another hypodermal-specific promoter, rol-6p,
driving lon-2(+) expression did not confer rescue of the
long phenotype. However, elt-3 and rol-6 are expressed
at different times, and this may explain the difference in
their ability to rescue the lon-2(lf) phenotype [19, 20].
These results indicate that LON-2 functions at the level
of hypodermal cells, which receive the DBL-1 signal, to
restrict pathway activity.
Interestingly, the dbl-1 pathway has been linked to the
nematode innate immune response [21, 22], and the in-
testine is a focus of this action [23]. Notably, the DBL-1
pathway genes sma-6, daf-4, sma-3, and lon-1 are
also expressed in the intestine [4, 5, 8, 16–18]. Based
on these observations and the fact that lon-2 is strongly
expressed in the intestine, lon-2 expression in this tis-
sue may function to regulate DBL-1-mediated innate
immune responses.
lon-2(lf) Animals Are Rescued by Drosophila
Glypican Gene dally
Dally, a Drosophila glypican, exhibits low conservation
to LON-2 throughout the length of the protein, and the
glypican motifs are entirely conserved (Figure S1). dally
mutations result in flies with abnormal cell-division pat-
terning, a result of genetic interactions with dpp [24, 25],
wingless [24, 26, 27], and hedgehog signaling pathways
Table 5. lon-2 cDNA without a Putative Integrin-Binding Site
Rescues lon-2(e678)
Genotype
Body Length
(% e678 695% c.l.) n
lon-2(e678) 100 6 4 24
lon-2(e678);wkEx75
[lon-2p::lon-2(RGD->RGA)]
74 6 3 24
Table 6. lon-2 Is Epistatic to HSPG-Modifying Enzyme Mutants
Genotype
Body Length
(% WT 695% c.l.) n
Wild-type 100 6 3 25
hse-5(tm472) 84 6 2 23
hse-5(tm472);lon-2(e678) 99 6 3 35
hst-2(ok595) 84 6 3 23
hst-2(ok595);lon-2(e678) 113 6 3 32
hst-6(ok273) 88 6 3 32
hst-6(ok273) lon-2(e678) 123 6 3 30
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proliferation through BMP and FGF signaling [30]. Muta-
tions in this gene lead to Simpson-Golabi-Behmel syn-
drome, an overgrowth syndrome associated with an in-
creased risk of forming certain tumors [31]. We asked
whether Dally could functionally substitute for LON-2
in C. elegans. We drove Drosophila dally cDNA tran-
scription from the lon-2 promoter in lon-2(e678) animals.
Transgenic animals were rescued to the wild-type body
Table 7. Hypodermal Expression of lon-2(+) Rescues lon-2(e678)
Genotype Expressed in
Body Length
(% WT or
e678 695% c.l.) n
lon-2(e678) 100 6 2 55
lon-2(e678);wkEx72
[lon-2p::lon-2]
78 6 2 17
lon-2(e678);wkEx73
[lon-2p::lon-2]
78 6 2 32
lon-2(e678);wkEx85
[elt-2p::lon-2]
Intestine 92 6 2 26
lon-2(e678);wkEx86
[elt-2p::lon-2]
Intestine 98 6 2 15
lon-2(e678);wkEx82
[elt-3p::lon-2]
Hypodermis 76 6 3 41
lon-2(e678);wkEx79
[rol-6p::lon-2]
Hypodermis 94 6 4 31
lon-2(e678);wkEx80
[rol-6p::lon-2]
Hypodermis 90 6 3 23size (Table 8), thereby showing functional conservation
between highly diverged Drosophila and C. elegans gly-
picans.
LON-2 Binds BMP2 Ligand
To understand mechanistically how LON-2 regulates
DBL-1 signaling, we asked whether LON-2 directly binds
DBL-1. Because GPI-linked proteins are often insoluble,
we eliminated the LON-2 GPI-anchor sequence by con-
structing a KpnI site by site-directed mutagenesis (50-
GGTTCA-30 to 50-GGTACC-30), removing the C-terminal
65 amino acids, and adding the LET-23 transmembrane
domain and a C-terminal T7 epitope tag (LON-2TM).
LON-2TM was cloned into a mammalian expression
vector and used to transfect 293T cells. When LON-2
was expressed in mammalian cells, the major form
of the protein detected by western-blot analysis
was the 150 kDa form (M2, Figure 2B), which likely re-
flects LON-2 modified by N-linked glycosylation and
Table 8. lon-2(e678) Is Rescued by Drosophila Dally cDNA
Genotype
Body Length
(% WT or e678 695% c.l.) n
lon-2(e678) 100 6 2 22
lon-2(e678);wkEx74
[lon-2p::dally]
85 6 3 18Figure 2. LON-2 Binds Directly to BMP2
(A and B) 293T cells were transiently trans-
fected with an empty vector (Lane 1), LON-
2TM(C322Y) (Lane 2), or LON-2TM (Lanes 3,
4, and 5) and incubated with 0.5 nM 125I-
BMP2. Specificity of LON-2 binding was as-
sayed by competition with 50 nM (1003 ex-
cess) unlabeled BMP2 (Lane 4) or BMP7
(Lane 5). Lysates were collected and immu-
noprecipitated with T7 antibody. Samples
were split and separated on SDS-PAGE gels
and exposed to film for visualization of 125I-
BMP2 (A) or immunoblotted with T7 antibody
for visualization of LON-2TM (B). Three forms
of the LON-2 protein were detected: a core
protein at approximately 62 kDa, an N-glyco-
sylated form at 70 kDa (M1), and a second 150
kDa (M2) modified form, which is N-glycolsy-
lated and heparin-sulphate modified. The
LON-2(C322Y) M2 band (C322Y M2) has a re-
duced size, consistent with a loss of N-glyco-
sylation of the protein.
(C) 125I signals were quantitated and normal-
ized to LON-2TM protein expression levels.
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163glycosaminoglycans. This is consistent with previous
studies, which revealed that Dally is modified by hep-
aran sulfate [17]. We also observed low levels of a 62
kDa and a 70 kDa form of LON-2 (Core and M1, respec-
tively, Figure 2B). The former is likely the unmodified
protein core of LON-2, whereas the latter may reflect
an N-glycosylated form of LON-2.
In the absence of readily available purified DBL-1, we
used mammalian iodinated BMP2, which binds the
C. elegans DBL-1 receptors SMA-6 and DAF-4 (data
not shown and [32]), and asked whether it would bind
to LON-2TM. We found that LON-2TM bound 125I-
BMP2 specifically, being efficiently competed by an ex-
cess of unlabeled BMP2, but less efficiently by BMP7
(binding is decreased to 27% or 43% of LON-2TM levels,
respectively) (Figures 2A and 2C). Consistent with our
results, it has recently been shown that Drosophila Dally
binds BMP4 [33]. We also introduced the lon-2(e2140)
mutation (C322Y) in the context of LON-2TM and asked
whether it affected ligand binding. This mutation re-
duced BMP2 binding to 36% of the binding observed
with LON-2TM (Figures 2A and 2C). The C322Y mutation
also affected the posttranslational modification of the
protein and resulted in a relative increase in the amount
of the core protein observed and a loss of the 70 kDa
modified form (Figure 2B). Consistent with a loss of the
70 kDa modification, there was a shift in the size of the
heparin-sulfated form of LON-2(C322Y) (C322Y M2), al-
though the amount of sulfated protein appeared to be
similar (Figure 2B).
Taken together, these data indicate that LON-2 exerts
its function in body-size control by modulating BMP sig-
naling. We propose that LON-2 binds and acts as a reser-
voir for DBL-1, sequestering it and attenuating the
strength of the signal in a dose-dependent manner.
This is the first identification of a glypican acting on
BMP signaling in C. elegans and establishes this model
system for the study of extracellular regulation of
growth-factor signaling. This is also the first case in
which direct binding of BMP ligand to this family of
HSPG has been shown inC. elegansand provides a basis
for a more mechanistic understanding of glypican regula-
tion. Further investigation of the mechanism of LON-2 ac-
tion should provide insights into how the ligand/LON-2
complex interacts with receptors and affects signaling.
Supplemental Data
Supplemental Data include Experimental Procedures and one figure
and can be found with this article online at http://www.current-
biology.com/cgi/content/full/17/2/159/DC1/.
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